PG 931Potent and selective MC4 receptor agonist CAS# 667430-81-1 |
- RVX-208
Catalog No.:BCC4475
CAS No.:1044870-39-4
- I-BET-762
Catalog No.:BCC4474
CAS No.:1260907-17-2
- Bromodomain Inhibitor, (+)-JQ1
Catalog No.:BCC1132
CAS No.:1268524-70-4
- I-BET151 (GSK1210151A)
Catalog No.:BCC4476
CAS No.:1300031-49-5
- CPI-203
Catalog No.:BCC4099
CAS No.:1446144-04-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 667430-81-1 | SDF | Download SDF |
PubChem ID | 134812824 | Appearance | Powder |
Formula | C59H85N15O11 | M.Wt | 1180.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 2 mg/ml in 25% ethanol / water | ||
Sequence | XDPFRWKPV (Modifications: X-1 = Ac-Nle, Phe-4 = D-Phe, Val-9 = C-terminal amide, Asp-2, Lys-7, Cyclized) | ||
Chemical Name | (2S)-1-[(3S,11S,17S,20S,23S)-3-(2-acetamidohexanoylamino)-20-benzyl-17-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-2,5,13,16,19,22-hexaoxo-1,6,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carbonyl]-N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]pyrrolidine-2-carboxamide | ||
SMILES | CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CCCN2C1=O)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N6CCCC6C(=O)NC(C(C)C)C(=O)N)NC(=O)C | ||
Standard InChIKey | WOFDJLFPEWSAPJ-MZDPDKPZSA-N | ||
Standard InChI | InChI=1S/C59H85N15O11/c1-5-6-20-40(66-35(4)75)51(78)71-45-32-48(76)63-26-13-12-22-42(57(84)73-28-16-25-47(73)56(83)72-49(34(2)3)50(60)77)68-54(81)44(31-37-33-65-39-21-11-10-19-38(37)39)69-52(79)41(23-14-27-64-59(61)62)67-53(80)43(30-36-17-8-7-9-18-36)70-55(82)46-24-15-29-74(46)58(45)85/h7-11,17-19,21,33-34,40-47,49,65H,5-6,12-16,20,22-32H2,1-4H3,(H2,60,77)(H,63,76)(H,66,75)(H,67,80)(H,68,81)(H,69,79)(H,70,82)(H,71,78)(H,72,83)(H4,61,62,64)/t40?,41-,42-,43-,44?,45-,46-,47-,49-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective melanocortin 4 (MC4) receptor agonist (IC50 values are 0.58 and 55 nM for human MC4 and MC3 receptors respectively). Produces a rapid and dose dependent restoration of cardiovascular and respiratory function in hemorrhage-shocked rats. |
PG 931 Dilution Calculator
PG 931 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 5-Hydroxy-7-acetoxyflavone
Catalog No.:BCN4217
CAS No.:6674-40-4
- DBU
Catalog No.:BCC2840
CAS No.:6674-22-2
- 3-Nitro-L-tyrosine ethyl ester hydrochloride
Catalog No.:BCN1384
CAS No.:66737-54-0
- E-64
Catalog No.:BCC1222
CAS No.:66701-25-5
- 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione
Catalog No.:BCC8786
CAS No.:666816-98-4
- Polygalacin D
Catalog No.:BCN3861
CAS No.:66663-91-0
- Platycodin D2
Catalog No.:BCN3847
CAS No.:66663-90-9
- Esculentoside H
Catalog No.:BCN2795
CAS No.:66656-92-6
- 7-Hydroxyflavone
Catalog No.:BCN3673
CAS No.:6665-86-7
- 5,7-Diacetoxyflavone
Catalog No.:BCN4216
CAS No.:6665-78-7
- Galangin 3-methyl ether
Catalog No.:BCN3681
CAS No.:6665-74-3
- 4',5-Dihydroxyflavone
Catalog No.:BCN4215
CAS No.:6665-67-4
- GSK-3 Inhibitor IX (BIO)
Catalog No.:BCC4510
CAS No.:667463-62-9
- BIO-acetoxime
Catalog No.:BCC6076
CAS No.:667463-85-6
- MeBIO
Catalog No.:BCC3898
CAS No.:667463-95-8
- NSC 109555 ditosylate
Catalog No.:BCC7540
CAS No.:66748-43-4
- Diosbulbin D
Catalog No.:BCN4218
CAS No.:66756-57-8
- 6,8-Diprenylorobol
Catalog No.:BCN4602
CAS No.:66777-70-6
- Esculin Sesquihydrate
Catalog No.:BCC8324
CAS No.:66778-17-4
- Platycodin A
Catalog No.:BCN7997
CAS No.:66779-34-8
- Impurity B of Calcitriol
Catalog No.:BCC1645
CAS No.:66791-71-7
- Syringaresinol-di-O-glucoside
Catalog No.:BCN2600
CAS No.:66791-77-3
- (+/-)-Forbesione
Catalog No.:BCN6423
CAS No.:667914-50-3
- Hernandezine
Catalog No.:BCN7793
CAS No.:6681-13-6
Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage.[Pubmed:17245369]
Br J Pharmacol. 2007 Mar;150(5):595-603.
BACKGROUND AND PURPOSE: In circulatory shock, melanocortins have life-saving effects likely to be mediated by MC4 receptors. To gain direct insight into the role of melanocortin MC4 receptors in haemorrhagic shock, we investigated the effects of two novel selective MC4 receptor agonists. EXPERIMENTAL APPROACH: Severe haemorrhagic shock was produced in rats under general anaesthesia. Rats were then treated with either the non-selective agonist [Nle4, D-Phe7]-melanocyte-stimulating hormone (NDP--MSH) or with the selective MC4 agonists RO27-3225 and PG-931. Cardiovascular and respiratory functions were continuously monitored for 2 h; survival rate was recorded up to 24 h. Free radicals in blood were measured using electron spin resonance spectrometry; tissue damage was evaluated histologically 25 min or 24 h after treatment. KEY RESULTS: All shocked rats treated with saline died within 30-35 min. Treatment with NDP--MSH, RO27-3225 and PG-931 produced a dose-dependent (13-108 nmol kg-1 i.v.) restoration of cardiovascular and respiratory functions, and improved survival. The three melanocortin agonists also markedly reduced circulating free radicals relative to saline-treated shocked rats. All these effects were prevented by i.p. pretreatment with the selective MC4 receptor antagonist HS024. Moreover, treatment with RO27-3225 prevented morphological and immunocytochemical changes in heart, lung, liver, and kidney, at both early (25 min) and late (24 h) intervals. CONCLUSIONS AND IMPLICATIONS: Stimulation of MC4 receptors reversed haemorrhagic shock, reduced multiple organ damage and improved survival. Our findings suggest that selective MC4 receptor agonists could have a protective role against multiple organ failure following circulatory shock.
Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5.[Pubmed:14531843]
J Pept Res. 2003 Nov;62(5):199-206.
The melanocortin system is involved in the regulation of several diverse physiologic pathways. Recently we have demonstrated that replacing His6 by Pro6 in the well-known antagonist SHU-9119 resulted in a potent agonist at the hMC5R (EC50 = 0.072 nm) with full antagonist activity at the hMC3R and the hMC4R. We have designed, synthesized, and pharmacologically characterized a series of peptide analogs of MT-II and SHU-9119 at the human melanocortin receptors MC3R, MC4R and MC5R. All these peptides were modified at position 6 with a Pro instead of a His residue. In this study, we have identified new scaffolds which are antagonists at the hMC4R and hMC3R. Additionally, we have discovered a new selective agonist at the hMC4R, Ac-Nle-c[Asp-Pro-D-Phe-Arg-Trp-Lys]-Pro-Val-NH2 (6, PG-931) which will be useful in further biologic investigations of the hMC4R. PG-931 was about 100-fold more selective for the hMC4R vs. the hMC3R (IC50 = 0.58 and 55 nm, respectively). Some of these new analogs have exceptional biologic potencies at the hMC5R and will be useful in further efforts to differentiate the substructural features responsible for selectivity at the hMC3R, hMC4R, and hMC5R.